To evaluate the effect of granulocyte/colony-stimulating factor (G-CSF) on the onset of the adult respiratory distress syndrome (ARDS), we investigated whether the incidence of ARDS due to pulmonary infection differed between the G-CSF group which received chemotherapy with G-CSF and historical controls without G-CSF. We evaluated 132 patients with hematological malignancy in complete remission without any main organ dysfunction who had been treated between April 1983 and December 1997. We compared the incidence of ARDS due to pulmonary infection between those who received G-CSF and those who did not. There was no remarkable difference in the number of patients, gender, age, or distribution of primary diseases between the two groups. The intensity of chemotherapy was not considered to significantly differ between the two groups, though the chemotherapy regimens administered differed slightly. In the G-CSF group, the duration of neutropenia was significantly shorter and the frequency of documented infection was significantly decreased. We could not find any relationship between ARDS due to pulmonary infection and any anticancer agent or antibiotics. There was no relationship between the kind of G-CSF and the incidence of ARDS due to pulmonary infection (per chemotherapy session; p > 0.10, per case; p > 0.30, χ2 test). The incidence of ARDS due to pulmonary infection per chemotherapy session was 4.21%, and showed a higher tendency in the G-CSF group (p < 0.100, χ2 test). The incidence of ARDS due to pulmonary infection per case was 25.4% and was significantly higher in the G-CSF group (p < 0.025, χ2 test). The incidence of ARDS due to pulmonary infection was higher in the G-CSF group than in the controls, suggesting that G-CSF promotes the development of ARDS due to pulmonary infection.

1.
Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871–877.
2.
Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J: Granulocyte colony-stimulating factor and neutrophil recovey after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;ii:891–895.
3.
Rinaldo JE, Borovetz H: Deterioration of oxygenation and abnormal lung microvascular permeability during resolution of leukopenia in patients with diffuse lung injury. Am Rev Respir Dis 1985;131:579–583.
4.
Weiss SJ, Curnutte JT, Regiani S: Neutrophil-mediated solubilization of the subendothelial matrix: Oxidative and nonoxidative mechanisms of proteolysis used by normal and chronic granulomatous disease phagocytes. J Immunol 1986;136:636–641.
5.
Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM: Lung neutrophils in the adult respiratory distress syndrome: Clinical and pathophysiologic significance. Am Rev Respir Dis 1986;133:218–225.
6.
Tate RM, Repine JE: Neutrophils and adult respiratory distress syndrome. Am Rev Respir Dis 1983;128:552–559.
7.
Hierholzer C, Kelly E, Lyons V, Roedling E, Davies P, Billiar TR, Tweardy DJ: G-CSF instillation into rat lungs mediates neutrophil recruitment, pulmonary edema, and hypoxia. J Leukoc Biol 1998;63:169–174.
8.
Matute-Ballo G, Liles WC, Radella F II, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR: Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;156:1969–1977.
9.
Murray JF, Matthay A, Luce JM, Flick MR: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720–723.
10.
Heyll A, Aul C, Gogolin F, Thomas M, Arning M: Granulocyte colony-stimulating factor treatment in a neutropenic leukemic patient with diffuse interstitial pulmonary infiltrates. Ann Hematol 1991;63:328–332.
11.
Lee CT, Fein AM, Lippmann M, Holtzman H, Kimbel P: Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. N Engl J Med 1981;304:192–196.
12.
McGuire WW, Spragg RG, Cohen AB, Cochrane CG: Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest 1982;69:543–553.
13.
Fowler AA, Walchak S, Giclas PC, Henson PH, Hyers TM: Characterization of antiproteinase activity in the adult respiratory distress syndrome. Chest 1982;81:50S–51S.
14.
Yoshida A, Kuramitsu K, Aoki H, Nagata M, Kikuchi H: Study on polymorphonucleocytal elastase-α-1-protease inhibitor complex in bronchoalveolar lavage fluid (BALF). Jpn J Med 1988;27:60–63.
15.
Matheson NR, Wong PS, Travis J: Enzymatic inactivation of human α-1-proteinase inhibitor by neutrophil myeloperoxidase. Biochem Biophys Res Commun 1979;88:402–409.
16.
Ismail G, Morganroth ML, Todd RF III, Boxer LA: Prevention of pulmonary injury in isolated perfused rat lungs by activated human neutrophils preincubated with anti-Mol monoclonal antibody. Blood 1987;69:1167–1174.
17.
Simon RH, DeHart PD, Todd RF III: Neutrophil-induced injury of rat pulmonary alveolar epithelial cells. J Clin Invest 1986;78:1375–1386.
18.
Ravoet C, Feremans W, Husson B, Majois F, Kentos A, Lambermont M, Wallef G, Capel P, Beauduin M, Delannoy A: Clinical evidence for an engraftment syndrome associated with early and step neutrophil recovery after autologous blood stem cell transplantation. Bone Marrow Transplant 1996;18:943–947.
19.
Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacobs HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977;296:769–774.
20.
Arnaout MA, Hakim RM, Todd RF III, Dana N, Colten HR: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985;312:457–462.
21.
Guiot HFL, Peters Wg, Broek PJ, Meer JWM, Kramps JA: Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicilin. Infection 1990;18:131–137.
22.
Vansteenkiste JF, Boogaerts MA: Adult respiratory distress syndrome in neutropenic leukemia patients. Blut 1989;58:287–290.
23.
Ognibene FP, Martin SE, Parker MM, Schlesinger T, Roach P: Adult respiratory distress syndrome in patients with severe neutropenia. N Engl J Med 1986;315:547–551.
24.
Malik AB: Pulmonary microembolism and lung vascular injury and edema. Am Rev Respir Dis 1987;136:467–470.
25.
Matthews JH: Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: Possible synergy. Lancet 1993;342:988–989.
26.
Iki S, Yoshinaga K, Ohbayashi Y, Urabe A: Cytotoxic drug-induced pneumonia and possible augmentation by G-CSF – Clinical attention. Ann Hemtol 1993;66:217–218.
27.
Bastion Y, Reyes F, Bosly A, Gisselbrecht C, Yver A: Possible toxicity with the association of G-CSF and bleomycin. Lancet 1994;343:1221–1222.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.